Evaluation of the cardioprotective potential of extracellular vesicles – a systematic review and meta-analysis

Sebastian Wendt1,2, Andreas Goetzenich1,2, Claudia Goettsch3, Christian Stoppe3,4, Christian Bleilevens5, Sandra Kraemer1,2 & Carina Benstoem2,4

Cardiovascular diseases are the main cause of death worldwide1. Reduced reperfusion and/or occlusion of the coronary arteries caused e.g. by atherosclerotic plaques results in reduced blood supply of distinct regions of the heart. This in turn, leads to hypoxia and cell death in the myocardium, commonly known as MI demanding an intervention to restore the blood supply of the infarcted region. Controversially, the reperfusion itself causes further damage due to emerging production of reactive oxygen species (ROS) as well as inflammation resulting in ischemia reperfusion (I/R) injury2. To counteract these damaging effects, numerous studies investigated the cardioprotective impact and underlying mechanisms of different protective treatments, such as conditioning by ischemia or anaesthetics3–5. In this context, extracellular vesicles (EVs) recently gained attention as promising mediators of cardioprotection. EVs are nanometer sized vesicles, which are released by almost every cell in the human body. Exosomes, the smallest group of EVs (30–150 nm), are generated by multiple inward folding of the plasma membrane and are released by fusion of multivesicular bodies (MVBs) with the plasma membrane. Microvesicles are generated through direct budding from the plasma membrane and have a size of 150–1000 nm. The largest type of vesicles are apoptotic bodies with a range of 1–5 μm6. It has recently been shown that EVs, especially small EVs (sEVs, exosomes and microvesicles), mediate cardioprotective abilities by transferring cytoprotective proteins and miRNAs7–9. For instance, heat shock protein 70 (HSP70) as well as miR-22 can be encapsulated in EVs and trigger pro-survival pathways in the recipient cells to protect those from cell death7,10.
We therefore investigated the beneficial effects that EVs might transmit to the heart in a systematic review and meta-analysis conducted in accordance with Cochrane standards. We categorized studies according to EV source, information of the applied EV-purification method, size of the isolated EVs, applied injury model as well as the specific mediator mediating protection inside the EVs. Studies that identified protective EVs were further investigated according to the used methods to identify their protective properties. Finally, a meta-analysis characterized the quality of effect.

Results

Study selection process. Figure 1 represents the process of study selection. According to the search criteria specified in the material and methods section, we identified 110 articles (34 from PubMed, 71 from web of science and 5 from Cochrane). 10 additional articles were found independently from other sources. 20 duplicates were removed. After reviewing title and abstract, we excluded 45 articles, as they did not match our inclusion criteria. We assessed 55 articles during full text screening, 43 were deemed suitable for qualitative analysis and included in this systematic review. Due to heterogeneity throughout the performed experiments in the investigated articles, only four studies were included in the meta-analysis.

Included studies. The included studies investigated EVs associated with cardioprotection. We first evaluated the quality of EV research by investigating the basic EV-specific experiments (electron microscopy (EM)-images and EV marker). We distinguished the studies by the EV source and extracted which EV purification protocol was used, the EV size, the applied injury model and if applicable the specific mediator inside EVs which mediated the protection. We additionally extracted which experiments were performed to investigate the protective properties of EVs and the investigated EV marker.

Quality of EV research. The publications were evaluated by basic criteria such as the chosen EV-purification methods, detection of EV related proteins as well the availability of EM pictures. These are our, in accordance with others, minimum criteria which have to be met to ensure an appropriate evaluation if the isolated particles were indeed EVs11,12.

The main purification procedures were based on ultracentrifugation7,10,13–33 and precipitation methods10,13,18,21,24,29,34–49. Six publications used both methods for EV purification13,18,21,24,29 and five publications used other methods or explicit different additional methods, to isolate EVs20,29,33,50,51. Of all investigated articles only nine publications did not perform EM pictures of the isolated EV7,19,24,32,40,43,47,50,51 and three publications did not investigate if the isolated particles contained typical EV markers19,43,50. We additionally investigated whether the described methods were reported in the results section (reporting bias) and if any disclosures might have compromised the results (other bias) (Table 1).
In the following, we will sort the publications by the main source of EVs investigated in the studies and extracted the EV purification method (detailed description in supplemental part), size, injury model, if applicable the main effector in EVs as well as the investigated EV marker.

Results per EV source. Cardiomyocytes. Cardiomyocytes are, next to fibroblasts and endothelial cells, one of the most abundant cell types in the mammalian heart. Due to their importance in cardiac function, researchers are extensively studying their physiological properties as well as their capabilities to secrete EVs. Publications investigating cardiomyocyte derived EVs are summarized in Table 2.

Table 1. Appraisal of research method (EM images and EV marker) and risk of bias summary. + Indicates that the desired information is available. – The information is not available. ? No statement about disclosure/conflict of interest present. * Disclosure statement/conflict of interest is positive but does not affect, in our understanding, the results.

In the following, we will sort the publications by the main source of EVs investigated in the studies and extracted the EV purification method (detailed description in supplemental part), size, injury model, if applicable the main effector in EVs as well as the investigated EV marker.

Results per EV source. Cardiomyocytes. Cardiomyocytes are, next to fibroblasts and endothelial cells, one of the most abundant cell types in the mammalian heart. Due to their importance in cardiac function, researchers are extensively studying their physiological properties as well as their capabilities to secrete EVs. Publications investigating cardiomyocyte derived EVs are summarized in Table 2.

Garcia et al. showed that starvation of the immortalized cardiomyocyte cell line H9c2 increased the secretion of EVs with altered composition and enhanced capability to induce tube formation. Borosch et al. investigated
the EV composition of primary cardiomyocytes and H9c2 cells after preconditioning with hypoxia or isoflurane which resulted in significantly altered cargo composition of the cell-derived EVs. A similar study confirmed that EVs from ischemic cardiomyocytes protected against oxidative-induced lesion, promoted angiogenesis and proliferation of endothelial cells in vitro. The authors suggested that miR-222 and miR-143, encapsulated in hypoxic EVs, are partially responsible for the pro-angiogenic effects. In vivo experiments confirmed enhanced angiogenesis due to hypoxic EV treatment after MI but no reduction of fibrosis was observed.

Zhong et al. identified HSP20, as a possible mediator of cardioprotection transferred by EVs. The authors postulated that HSP20-overexpressing primary cardiomyocytes secrete EVs with elevated levels of HSP20 compared to EVs from control cells. HSP20 additionally promoted proliferation, migration and tube formation. Unfortunately, due to methodological limitations in this study, not all observed effects can be attributed to HSP20 in EVs. Basic EV-related experiments such as EM-images and testing for EV markers were not conducted in this study.

In a following publication, the authors investigated whether cellular HSP20 overexpression and thereby elevated HSP20 levels in EVs might protect the myocardium in diabetes. Compared to EVs from control cells, EVs secreted from cardiomyocytes and HSP20 exhibited elevated levels of p-protein kinase B (pAkt), survivin and superoxide dismutase 1 (SOD1) and protected against hyperglycemia-triggered cell death.

Cardiac progenitor cells. Cardiac progenitor cells (CPCs) represent a heterogeneous group of cells throughout the heart and the surrounding vessels which can be activated upon injury and contribute to the cardiac renewal. Recent findings indicated that CPC-derived EVs might have a predominant role in transmitting cardioprotective mediators to the damaged heart. With our defined search criteria, we found four articles investigating the protective activity of CPC-derived EVs (Table 3).

Barile et al. isolated CPCs from patients who underwent heart valve surgery. Apoptosis was reduced in the starved and reperfused immortalized cardiomyocyte HL-1 cell line, which were treated with CPC-derived EVs. Additionally, tube formation in in human umbilical vein endothelial cells (HUVECs) and angiogenesis in vitro were enhanced by those EVs. In vivo experiments indicated that a treatment with EVs improved the left ventricular ejection fraction (LVEF) and reduced scar tissue after MI. Levels of miR-210 and miR-132, were elevated in CPC-derived EVs compared to EVs from fibroblasts. The authors suggested that these miRNAs down-regulate ephrin A3, protein-tyrosine phosphatase 1 (PTP1) and RasGTPase-activating protein (RasGap)-p120 and thereby transduced their beneficial effects in the recipient cells and tissue.

In a similar study, the authors challenged H9c2 cells with H2O2 and performed an in vivo model of I/R injury. CPC-derived EVs were again able to attenuate apoptosis, reduced the amount of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) positive cells and pro-apoptotic caspase 3/7 activation. Additionally, the transcription factor GATA4-responsive miR-451 was overexpressed in CPC-derived EVs.

Xiao et al. used an oxidative stress model to assess the protective properties of CPC-derived EVs. First, the authors observed that H2O2-stressed CPCs secreted more EVs and the cargo of those EVs was also altered compared to EVs derived from untreated cells. EVs from treated cells contained increased levels of miR-21, targeting

| Ref. | PM | Size | Injury model | Main effector | EV marker |
|------|----|------|--------------|---------------|-----------|
| Garcia et al. | UC, sucrose cushion, precipitation | 50–100 nm | NSI | NSI | CD63, CD9, CD81 |
| Borosch et al. | Size-exclusion chromatography, UC | 150 nm | NSI | NSI | Alix, HSP70, CD63, Flot-1, CD81 |
| Ribeiro-Rodrigues et al. | UC | 111-137 nm | MI, H2O2, miR-222, miR-143 | Alix, HSP70, CD63, Flot-1, TSG-101, CD81, GAPDH |
| Zhang et al. | Precipitation | 54.9–55.2 nm | Streptozotocin induced diabetes | HSP20 | CD63, CD81, HSP70 |

**Table 2.** Publications investigating EVs from cardiomyocytes. EV-purification method (PM), particle size, investigated injury model, main effector mediating protection are stated and EV marker. UC = ultracentrifugation; HSP = heat shock protein; MI = myocardial infarction; NSI = not specifically indicated; Ref. = reference; TSG = tumour susceptibility gene; Flot = flotillin; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; *self-assessed (assumption made from EM images).

| Ref. | PM | Size | Injury model | Main effector | EV marker |
|------|----|------|--------------|---------------|-----------|
| Barile et al. | Precipitation, UC | 30–90 nm | Starvation, MI | miR-210, miR-132, CD63 | CD63, CD9, CD81 |
| Chen et al. | Precipitation | 40–100 nm | H2O2, I/R-injury | miR-451 | CD63 |
| Xiao et al. | Precipitation | 50–150 nm | H2O2 | miR-21 | Alix, CD63, CD9 |
| Gray et al. | UC | 96–102 nm | I/R injury | (11 miRNAs) | CD9 |

**Table 3.** Publications investigating EVs from cardiac progenitor cells (CPCs). EV-purification method (PM), particle size, investigated injury model, main effector mediating protection and EV marker are stated. I/R = ischemia/reperfusion; UC = ultracentrifugation; MI = myocardial infarction; NSI = not specifically indicated; Ref. = reference.
programmed cell death protein 4 (PDCD4), which is involved in apoptosis. The authors could show that H9c2 cells, which were pre-treated with CPC-derived EVs, were more resistant to H$_2$O$_2$ treatment. Interestingly, EVs from pre-treated source were even more protective, presumably due to the elevated miR-21 levels and thereby reduced PDCD4 levels in the recipient cells.

Gray et al. investigated EVs derived from hypoxia stimulated CPCs, that were able to promote tube formation and decreased profibrotic gene expression. Hypoxic treatment of the cells indeed altered the EV composition. 11 miRNAs were upregulated in EVs derived from hypoxic CPCs compared to EVs, which were isolated from normoxic cells. Additionally, those EVs were able to improve cardiac function in a model of I/R-injury. EVs from CPCs, which were previously subjected to 12 h hypoxia, were able to reduce fibrosis in vivo. EVs from cells, which were not treated with hypoxia or experienced a shorter treatment, had attenuated effects.

Cardiosphere derived cells. Cardiac surgical biopsy specimens exhibit the potential of secreting a heterogeneous population of cardiac cells called cardiosphere derived cells (CDCs). Publications matching our search criteria and investigating EVs from these cells are stated in Table 4.

EVs from CDCs inhibited apoptosis and promoted proliferation in neonatal cardiomyocytes. In vivo data also demonstrated reduced scar mass, resulting in elevated contractility and increased viable mass in a MI-injury model upon treatment with CDC-derived EVs. Blocking the generation of EVs with GW4869 also demonstrated reduced scar mass, resulting in elevated contractility and increased viable mass in a MI-injury model.

Fibroblasts. The main function of fibroblasts is to produce extracellular matrix and thereby stabilize the surrounding tissue. New studies attribute those cells to far more complex signalling within the heart which is in part based on EVs. Recent findings indicated that fibroblast-derived EVs might contribute to cell migration and proliferation of cardiac fibroblasts whereas others demonstrated a detrimental impact. Publications matching our search criteria and investigated fibroblast-derived EVs are summarized in Table 5.

Cardiac fibroblast-derived EVs induced pathological hypertrophy in cardiomyocytes in vitro. miR-21-3p was identified as specific mediator in those EVs which targets sorbin and SH3 domain-containing protein 2 (SORBS2) and PDZ and LIM domain 5 (PDLIM5) inducing hypertrophy. Others showed that EVs from fibroblasts had diminished protective capabilities. Ibrahim et al. demonstrated the benefits of EVs from cardiosphere derived cells (CDCs) by different in vivo and in vitro experiments. In contrast, normal human dermal fibroblasts (NHDFs) were not able to transmit comparable protection. These findings were supported by others. Wang et al. additionally supported this notion by demonstrating that EVs from induced pluripotent stem cells (IPS) were able to protect against myocardial I/R-injury while EVs from cardiac fibroblast had a diminished effect.

Mesenchymal stem cells. Mesenchymal stem cells (MSCs) are adult stem cells with the potential to differentiate into multiple other cell types. The tremendous capabilities of MSCs are also attributed to their great potential of secreting important factors for the control of haematopoiesis or immunomodulation. We found several publications fitting our search criteria and investigated whether MSC-derived EVs promote protection (Table 6).

Feng and Co-workers identified miR-22 as potential cardioprotectant which was secreted via EVs from ischemic-preconditioned MSCs. EVs from these cells were able to reduce fibrosis in infarcted hearts. Methyl CpG binding protein (Mecp2) is a direct target of miR-22, which was enriched in the investigated EVs and contributed to reduced cardiac damage.

MSC-derived EVs also contributed to cardioprotection in a sepsis model induced by cecal ligation and puncture. EV treatment increased the ejection fraction of mice and improved the survival in polymicrobial sepsis. The authors could demonstrate that tumor necrosis factor-α (TNFα), interleukin 6 (IL-6) and IL-1β secretion was reduced in macrophages after the treatment with MSC-derived EVs in vitro. The authors attributed the cardioprotective properties to miR-223 from WT-MSC derived EVs and thereby targeting Semaphorin-3A (Sema3A).

| Ref. | PM | Size | Injury model | Main effector | EV marker |
|------|-----|------|--------------|--------------|-----------|
| Ibrahim et al. | Precipitation | 30–90 nm | MI | miR-146a | CD63 |
| Namazi, Namazi et al. | UC | 150–170 nm | cobalt chloride as hypoxia mimetic agent | NSI | CD63, CD81 |
| Namazi, Mohit et al. | UC | 140–180 nm | NSI | NSI | CD63, CD81 |
| de Couto et al. | Precipitation | 150 nm | I/R injury | miR-181b | CD63, Alix, Hop70 |

Table 4. Publications investigating EVs derived from cardiosphere derived cells. EV-purification method (PM), particle size, investigated injury model, main effector mediating protection and EV marker are stated. I/R = ischemia/reperfusion; UC = ultracentrifugation; MI = myocardial infarction; NSI = not specifically indicated; Ref. = reference; HSP = heat shock protein.

SciRep | (2018) 8:15702 | DOI:10.1038/s41598-018-33862-5

5
and signal transducer and activator of transcription 3 (Stat3)9. In addition to enhanced HUVEC tube formation and reduced fibrosis, Teng and co-workers could show that MSC-derived EVs reduced the inflammation in the infarcted area48. These results were supported by an in vivo model of MI where MSC-derived EVs increased cardiac stem cell tube formation and reduced fibrosis. The authors suggested that this distinct miRNA cargo might be the reason for the cardioprotective properties of MSC-derived EVs98. Additionally, in a model of MI, administration of EVs reduced cardiac damage and improved systolic function23.

In comparison to EVs from wild types, transfection enforced expression of specific proteins in host cells and might further enhance the resulting EV capabilities. EVs derived from MSC<sub>CXCR4</sub> were able to reduce caspase 3 activity and induced upregulation of IGF-1α and pAkt in neonatal cardiomyocytes36. Implantation of a cell patch, which was treated with EVs from MSC<sub>CXCR4</sub>, was significantly more potent to reduce the infarct size compared to cell patches with control EVs. These data provided evidence that the protectivity from MSC-derived EVs may be enhanced by specific cargo loading36. In addition, miR-221 was investigated as EV-mediated cardioprotective factor. Rat ventricle cardiomyocytes which were cultivated under hypoxic conditions were more robust against this stimulus when incubated with supernatant from MSC<sub>CXCR4</sub> 41. However, the experiments conducted in this study do not allow the conclusion that MSC-derived EVs are protective. For instance, isolated EVs were not transferred to other cells to investigate their ability of cytoprotection41. In a study conducted two years later, EVs which were treated with EVs from MSC<sub>CXCR4</sub>, was identified as the effector mediating the protection42. miR-19a targets phosphatase and tensin homolog (PTEN), inhibiting cell proliferation and induces apoptosis60. Even though the authors showed that EVs from MSC<sub>GATA-4</sub> mediated improved cell function and protection, EVs from control MSCs were still protective as well42. In an early study conducted in 2009, Lai and co-workers investigated the protective effects of EVs secreted from human embryonic stem cell-derived mesenchymal stem cells (HuES9.E1). Isolated EVs were able to reduce the infarct size after myocardial I/R injury20. The underlying signalling pathways include decreased oxidative stress as well as increased Akt and glucogen synthase kinase-3β (GSK-3β) phosphorylation (GSK-3β)96. EVs from, previously with H<sub>2</sub>O<sub>2</sub> treated, MSCs additionally contributed to reduced oxidative stress induced cell death by inhibition of PTEN. miR-21 was identified as key mediator of those protective properties48.

Table 5. Publications investigating fibroblast-derived EVs. EV-purification method (PM), particle size, investigated injury model, main effector mediating protection and EV marker are stated. UC = ultracentrifugation; MI = myocardial infarction; I/R = ischemia/reperfusion; UC = ultracentrifugation; NSI = not specifically indicated; Ref. = reference; TSG = tumour susceptibility gene; Flot = flotillin; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; *Self-assessed (Assumption from Supplemental Information).

| Ref. | PM | Size | Injury model | Main effector | EV marker |
|------|----|------|--------------|--------------|-----------|
| Bang et al.20 | UC | 50–100 nm | Left ventricular pressure overload | miR-21-3p | CD63, GAPDH |
| Ibrahim et al.25 | Precipitation | NSI | MI | NSI | CD63 |
| Y. Wang et al.40 | Precipitation | 100 nm | H<sub>2</sub>O<sub>2</sub>, I/R injury | NSI | CD63, TSG101 |
| Barlie et al.23 | Precipitation, UC | NSI | Starvation, MI | NSI | NSI |
| de Couto et al.46 | Precipitation | 150 nm<sup>*</sup> | I/R Injury | NSI | NSI |
| Borosch et al.33 | Size-exclusion chromatography | ≈150 nm | MI | NSI | Alix, HSP70, CD63, Flot-1, CD81 |

Table 6. Publications investigating EVs from mesenchymal stem cells. EV-purification method (PM), particle size, investigated injury model, main effector mediating protection and EV marker are stated. UC = ultracentrifugation; MI = myocardial infarction; I/R = ischemia/reperfusion; NSI = not specifically indicated; Ref. = reference; HSP = heat shock protein; GAPDH = glyceraldehyde 3-phosphate dehydrogenase *Self-assessed (assumption made from EM images).

| Ref. | PM | Size | Injury model | Main effector | EV marker |
|------|----|------|--------------|--------------|-----------|
| Feng et al.10 | UC/Precipitation | 30–120 nm | MI | miR-22 | CD63 |
| X. Wang et al.3 | UC, sucrose gradient | 10–100 nm | Sepsis/Inflammation | miR-223 | CD81, CD63 |
| Teng et al.30 | Precipitation | 50–100 nm | MI | NSI | CD63 |
| Zhang et al.46 | Precipitation | 11–98 nm | MI | NS | CD63, GAPDH |
| Zhao et al.32 | UC, sucrose cushion, ultrafiltration | 20–85 nm | In vitro hypoxia, MI | NSI | CD9, CD63 |
| Kang et al.10 | Precipitation | 40–90 nm | MI | CXCR4 | CD9, CD63 |
| Yu et al.31 | Precipitation | ≈100 m<sup>*</sup> | NSI | (miR-221) | CD9, CD63, HSP70 |
| Yu et al.32 | Precipitation | ≈100 nm | In vitro hypoxia, MI | miR-19a | CD9, CD63, HSP70 |
| Lai et al.20 | Size exclusion fractionation (UC, sucrose gradient, Immunoprecipitation) | 35–65 nm | I/R-injury | NSI | CD9, CD81, Alix |
| Arslan et al.30 | Ultrafiltration, Chromatography | NSI | I/R-injury | NSI | NSI |
| Shi et al.40 | Precipitation | 30–100 nm | H<sub>2</sub>O<sub>2</sub> | miR-21 | CD9, CD63, HSP70 |
Body fluids. In contrast to the previously investigated EV sources, the original sources of EVs in body fluids are diverse. Numerous publications were identified by our search criteria, studying EVs from different body fluids and are further investigated in the following (Table 7).

Vicencio et al. hypothesized that an established cardioprotective treatment has an impact on EVs and their cargo. The authors analysed whether blood derived EVs from a remote ischemic preconditioned (rIPC) donor were more protective than those from an untreated source. Surprisingly, several in vitro and in vivo experiments revealed that EVs from treated and untreated source were protective in a similar fashion. EVs in general were able to reduce cell death and ultimately the infarct size. The authors suggested that HSP70 on the EV surface, might interacted with toll-like receptor 4 (TLR-4) on the recipient cells, thereby triggering a signal cascade which activates intracellular HSP27 which further promotes cardioprotection. In a similar study, EVs from a rIPC group and the corresponding control group were isolated from serum and analysed. The predicted effector, miR-144 was not upregulated upon rIPC treatment in EVs but in the serum of the treated animals. In contrast, the precursor form of miR-144 was enriched in EVs. The authors suggested that miR-144 is important for cardioprotection but EVs are probably not the main carrier and mediator of this protective miRNA. A similar study revealed that EVs, isolated from rIPC-rats, could reduce the infarct size in a model of in vivo I/R injury. Minghua et al. supported these findings by demonstrating that EVs from rIPC rats decreased apoptosis in an in vitro H2O2 stress model as well as decreased infarct size in an I/R injury in vivo model. The authors suggested that miR-24 encapsulated in EVs is able to transduce the protective properties. A different approach investigated EV mediated protection in an ex vivo IPC Langendorff model. The perfusates from preconditioned rat hearts were collected and used to treat hearts prior to infarction. EV-depleted perfusates caused increased infarct size compared to the EV-containing perfusates. In another IPC study, the authors investigated whether this treatment might promote a change in the DNA content in EVs. The authors could not detect any difference in the number of sequenced gene fragments between treatment and control. In a rat model, rIPC resulted in an increase of miR-29a in serum-derived EVs. miR-29a is a key regulator of tissue fibrosis and the increase of this miRNA might contribute to the finding of reduced fibrosis after rIPC treatment. Nevertheless, the exclusive protectivity of EVs was not investigated. As mentioned previously, HSPs, in or on the surface of EVs, might mediate cardioprotection. Wang et al. developed a transgenic mouse model with cardiac specific overexpression of HSP20. EVs isolated from mouseHSP20 serum had higher HSP20 levels compared to EVs from control mice. The cardiac contractile function of diabetic mice with stable angina. Indeed, the authors identified several EV proteins which were upregulated upon MI in vitro. EVs from healthy donors instead did not. Similar results were obtained in a study subjecting healthy and diabetic rats to rIPC and evaluating the protectivity in an in vitro model of hypoxia reoxygenation. Cell death of HL-1 cells was reduced if treated with EVs from healthy rats but no effects were observed with EVs from diabetic rats.

An observational study was conducted in 2016, comparing the plasma EV cargo of patients with MI and patients with stable angina. Indeed, the authors identified several EV proteins which were upregulated upon MI. A similar study investigated in a porcine in vivo model the influence of ischemic preconditioning on EV cargo. EVs from preconditioned animals had an altered mRNA cargo related to proteins which are commonly associated with the protective effects of ischemic preconditioning.

Other cell types. Several studies which were found by our search criteria did not fit in the previously described groups. We will therefore describe the benefits of EVs from these sources in Table 8.

Table 7. Publications investigating EVs derived from several body fluids. EV-purification method (PM), particle size, investigated injury model, main effector mediating protection and EV marker are stated.

| Ref. | Source | PM | Size | Injury model | Main effector | EV Marker |
|------|--------|----|------|--------------|--------------|-----------|
| Vicencio et al. | Plasma | UC | 75 ± 2 nm rat plasma | I/R injury | HSP 70 | CD63, CD81, HSP70 |
| Li et al. | Serum | Precipitation | 50–400 nm | I/R injury | (miR-144) | CD63 |
| Ma et al. | Plasma | UC | 367.6 nm | I/R Injury | NSI | CD41, Annexin V |
| Minghua et al. | Plasma | Precipitation | 50–200 nm | H2O2 treatment, I/R injury | miR-24 | CD63, CD81, CD9 |
| Giricz et al. | Coronary perfusates | UC | 10–1000 nm | I/R injury | NSI | HSP60 |
| Svennerholm et al. | Plasma | UC, sucrose gradient | 30–350 nm | NSI | NSI | CD81 |
| Yamaguchi et al. | Serum | UC | NSI | Streptozotocin induced diabetes | HSP20 | NSI |
| X. Wang et al. | Serum | Precipitation | NSI | | HSP20 | NSI |
| Davidson et al. | Plasma | UC | ≤100 nm | Hypoxia reoxygenation | NSI | CD81, HSP70 |
| Wider et al. | Serum | UC | 0–200 nm | Hypoxia reoxygenation | NSI | Flot-1, HSP60 |
| Svennerholm et al. | Plasma | UC, sucrose gradient | 30–350 nm | NSI | NSI | CD81 |
| Cheow et al. | Plasma | UC | 50–100 nm | NSI | NSI | CD81, CD98 |
| Obata et al. | Plasma | Precipitation, UC | NSI | | NSI | Syntenin |
IPS cells transduce their beneficial properties also through EVs. In vitro experiments indicated that iPS-derived EVs inhibit proapoptotic caspase 3/7 activation after H₂O₂ treatment of H9c2 cells. The conducted experiments also identified two specific miRNAs miR-21 and miR-210 which potentially transmitted the cardioprotective properties of iPS cell-derived EVs although no confirmation experiments were performed. In an in vivo model of I/R injury, apoptosis of cardiomyocytes was additionally reduced after treatment with iPS-derived EVs.

Recently adipose tissue has proven to be a reliable source of stem cells. Kang et al. were able to show that EVs from adipose-derived stem cells (ASCs), preconditioned with endothelial differentiation medium, induced HUVEC tube formation. miR-31 was identified as mediator of these pro-angiogenic effects by targeting the factor-inhibiting hypoxia inducible factor-1 (FIH-1). Gu and co-workers performed several in vitro experiments to investigate whether EVs from endothelial progenitor cells (EPCs) might protect H9c2 cells from angiotensin II induced hypertrophy. Apoptosis and cell viability were improved by EPC-derived EVs. Additionally, the isolated EVs induced phosphorylation of Akt and endothelial nitric oxide synthase (eNOS) in angiotensin II treated H9c2 cells.

The beneficial effects of EVs from cardiac stem cells were investigated in a mouse model of doxorubicin induced dilated cardiomyopathy. Mice received cardiac stem cell-derived EVs which were able to improve cardiac function, reduce fibrosis in the myocardium as well as TUNEL positive cells, respectively DNA fragmentation.

Endothelial cells, overexpressing HIF-1 secreted EVs with higher contents of miR-126 and miR-210. The specific cargo of these EVs resulted in an activation of pro-survival kinases and induced a glycolytic switch in the recipient CPCs. EVs additionally reduced the cellular damage during hypoxic conditions. Human amniotic fluid stem cells (hAFS) secreted EVs which were able to mediate antiapoptotic effects in vitro. Hypoxia preconditioning of hAFS additionally enhanced the protectivity of EVs and furthermore modulated the miRNA cargo of those EVs. Surprisingly, EVs from HUVECs, cultivated under hyperglycaemic conditions, were not able to protect primary adult cardiomyocytes from hypoxia-reoxygenation whereas EVs from regular cultivated cells were protective. In a recent study, Obata demonstrated that adiponectin is able to stimulate ceramide secretion by EVs, reducing the intracellular level of ceramides.

Table 8. Publications investigating EVs from cells not fitting in the previously described categories. EV-purification method (PM), particle size, investigated injury model, main effector mediating protection and EV marker are stated. UC = ultracentrifugation; I/R = ischemia/reperfusion; NSI = not specifically indicated; Ref. = reference; TSG = tumour susceptibility gene; HSP = heat shock protein; *self-assessed (assumption made from nanoparticle tracking analysis).

| Ref.       | Source                                      | PM                | Size   | Injury model   | Main effector | EV marker |
|------------|---------------------------------------------|-------------------|--------|----------------|---------------|-----------|
| Y. Wang et al. | Induced pluripotent stem cells            | Precipitation    | 100 nm | I/R-injury     | (miR-21, miR-210) | CD63, TSG101 |
| T. Kang et al. | Adipose-derived stem cells                | UC                | <1 µm  | NSI            | miR-31        | Alix      |
| Gu et al.  | Endothelial progenitor cells              | UC                | NSI    | Angiotensin II-Induced hypertrophy | NSI         | NSI      |
| Ong et al. | Cardiac stem cells                        | Ultrafiltration   | 129.6 nm | doxorubicin induced cardiomyopathy | NSI         | CD63     |
| Vandergriff et al. | Induced pluripotent stem cells        | Precipitation    | 30–110 nm | Hypoxic stress in vitro | miR-126, miR-210 | CD63, CD9 |
| Balbi et al. | Human amniotic fluid stem cells           | UC                | 50–200 nm | Muscle atrophy, H₂O₂ | NSI         | TSG101, Alix, CD81, CD9, CD63, Annexin V |
| Davidson et al. | HUVECs                                   | UC                | ≈100 nm | Hypoxia reoxygenation | NSI         | CD81     |
| Obata et al. | Endothelial F2 cells                      | UC, density gradient, | ≈90 nm* | NSI            | Alix, HSP70, CD63 syntenin |

Summary of EV related benefits and meta-analysis. We additionally summarized the type of performed experiments to investigate the protective properties of EVs and recapitulated the beneficial outcomes in Table 9. Almost all EVs, from all sources, were able to mediate protection. Several publications investigated, whether overexpression of specific molecules results in EVs with enhanced protective properties e.g. enhanced angiogenesis or reduction of apoptosis. Others investigated the capabilities and characteristics of EVs secreted under regular conditions. Different treatments of the EVs source also enhanced EV properties. Researchers investigating fibroblast-derived EVs postulated that they might not contribute to cardioprotection in the same extent whereas other groups observed enhanced proliferation/migration after treatment with fibroblast-derived EVs. We summarized the major effector molecules mediating protective or detrimental properties in Fig. 2.

To evaluate whether the described properties of EVs are indeed cardioprotective we performed a meta-analysis. Pooling two independent studies which investigated the number of capillaries after EV treatment (Fig. 3) and two studies investigating the protective effect of EVs in a setting of hypoxia-reoxygenation (Fig. 4). Both analysis indicated significant effects favouring EV treatment.

Discussion. This is the first all-encompassing systematic review/meta-analysis investigating the cardioprotective effects of EVs. 43 studies were chosen for analysis and data extraction. We found that EVs derived from different cell types as well as from different body fluids, mediated beneficial properties. Only EVs from fibroblasts had, as described in some investigated studies, harmful effects and mediated hypertrophy. We evaluated the EV specific experiments, investigating the predominant mediators of protection carried by EVs and categorized the studies by...
EV source and the experiments performed to investigate the positive capabilities of EVs. We finally conducted a meta-analysis and verified the positive properties of EVs by combining the results of independent studies.

Investigating EVs and their beneficial properties is often challenging and several basic experiments are needed to ensure that the described effects in the corresponding investigation are transferred by EVs. Recommendations, first described in 2013, what kind of experiments are needed or which isolation or purifications methods are suitable to ensure an appropriate EV preparation were given by several publications. Nevertheless, some of these guidelines have been published only recently and several of the here included publications were published before these guidelines. These guidelines are constantly changing due to novel developments and new insights in the field of EV research, making it impossible to introduce guidelines for a broader group of researchers. Applying those, partly strict, criteria to all investigated publications in our review may therefore not be suitable. Nevertheless, EM images and identification of EV-marker are in our understanding mandatory in EV research.

EVs from numerous sources were successfully isolated by the included studies. Few studies did not perform the necessary experiments to ensure an appropriate EV preparation as described previously. We have to mention that the existing methods to verify EV properties are far from absolute. For instance, techniques to measure the concentration of EVs or to describe the morphological properties might not distinguish between EVs and particles with a similar size range, as reviewed by others. The indicated sizes, stated in the results part, have also to be considered as a range since EVs with only one size cannot be isolated so far. Only a variety of different experiments is suitable to absolutely ensure that the isolated particles are indeed EVs. Additionally, precipitation and basic ultracentrifugation methods might result in co-isolation of non-EV particles and thereby hold the risk for impurities. A study considering these problems was performed in 2016, investigating EV marker after different centrifugation steps in the resulting pellets. Due to the great variety and no gold standard EV purification protocol, we therefore only distinguished between UC, precipitation-based and other protocols in our systematic review. Further research and development of more appropriate methods for EV purification and detection of multiple EV sources are needed to ensure comparable results from different studies. We would like to point out that in some of the described studies immortalized cell lines such as H9c2 and HL-1 cells were used to investigate EV properties. For instance, undifferentiated H9c2 cells might not represent a cardiac specific phenotype and the results might therefore be met with caution.

The cardioprotective properties of EVs from different sources have been investigated by several studies included in this review. The main effector of these benefits are miRNAs such as miR-210 or miR-132, inhibiting apoptosis or enhancing tube formation. Especially miR-21 and miR-210 are encapsulated in EVs from numerous sources and mediated protection in different ways. The beneficial effects of EV-derived miRNAs in other diseases such as autoimmune hepatitis or sepsis has additionally shown by other groups. The conclusions whether EVs from genetically engineered cells, from a treated donor or regularly secreted are cardioprotective, are inconsistent. In several studies which investigated EVs from a genetically engineered origin, the EVs from control cells had also beneficial capabilities, even if the effects were not that distinct. These observations were also made in studies investigating the EVs from previously treated sources such as ischemic preconditioning. We therefore conclude that EVs in general are protective and that these properties might be enhanced by an appropriate treatment of the EV source or transfecion of the host cells. EVs from several body fluids have also been proven to mediate positive properties. These EVs might originate from different sources making it difficult to identify specific molecules mediating the protective effects. The results have therefore to be met with caution and further in vitro analysis might be needed to investigate which treatment triggers the release of EVs from a distinct cell type mediating the protection.

Even though the same cell types were investigated in different studies and similar experiments were performed to evaluate the EV mediated protection, a stringent meta-analysis was not possible due to the lack of consistency. Tube formation or cell survival experiments were conducted by numerous studies. But these, for example, were performed with MSC-derived EVs either from genetically engineered or wild type cells or with different tube forming cells. To evaluate exemplarily the protective properties of EVs, we combined the data of two studies performed with MSC-derived EVs either from genetically engineered or wild type cells or with different tube formation or cell survival experiments. The meta-analysis from two different studies conducted by the same group indicated that EVs protect cardiomyocytes from hypoxia/reoxygenation injury. Taken together, these findings demonstrate the urgent need for more consistency and adequately designed studies, not only for the EV-purification methods but also for the performed experiments investigating the effect of EVs.

Even though the protectivity of EVs has been proven in several in vitro and in vivo models the translation to humans will be a major challenge in the future. Unlike other approaches which failed to accomplish the translation from bench to bedside, the conserved mechanism of EV release and uptake in many species has the great potential that EVs might be of special use in the near future.

Conclusion

EVs are important mediators of cardiac protection and deliver specific molecules such as proteins and miRNAs to the recipient cells. The great majority of the investigated publications could proof the benefit of EVs especially by reducing cardiac damage or induction of angiogenesis. The inconsistency, in EV purification methods and experiments investigating EV mediated benefits, made it difficult to recapitulate data from different studies. Our evident conclusion is that EVs are important mediators of protection in cardiovascular diseases. These findings substantiate the assumption that EVs can serve as a potent therapeutic in the future. An urgent need, especially for a general EV-purification protocol, remains and has to be addressed in the future.
Methods

The methods used in this review are in accordance with the recommendations provided by the Cochrane Collaboration.

Criteria for considering studies for this review.  Types of studies.  We included experimental research studies, which investigated EVs in in vitro or in vivo models (animal and human). We did not differentiate between exosomes, microvesicles or apoptotic bodies as long as the vesicular origin and effect matched our inclusion criteria.

Types of interventions.  We included all studies, which investigated the protective effect of EVs. We did not further restrict type of intervention as long as the assumed protective effects of EVs or EV-derived components were the main focus of the study.

Search methods for identification of studies.  We identified trials through systematic searches of the following bibliographic databases on May 24th, 2018:

| EV source | Publication | Cardiac damage | Apoptosis/cell death | Caspase activation | Proinflammatory mediators | LDH release/Activity | Ejection fraction | Protective kinases | Proliferation/Migration | Tube formation/cell survival |
|-----------|-------------|----------------|---------------------|-------------------|--------------------------|---------------------|------------------|------------------|--------------------------|-----------------------------|
| CPCs      | Barile et al. | X | X | X | X | X |
| Chen et al. | X | X | X |
| Xiao et al. | X | X |
| Gray et al. | X |
| CDCs      | Namazi, Namazi et al. | X | X |
| Ibrahim et al. | X | X | X | X | X |
| Namazi, Mohit et al. | X | X | X |
| de Couto et al. | X | X | X | X |
| MSCs      | Feng et al. | X | X |
| X. Wang et al. | X | X | X | X | X |
| Kang et al. | X | X | X | X | X |
| Teng et al. | X | X | X | X | X |
| Zhang et al. | X |
| Zhao et al. | X | X |
| Yu et al. | X | X | X | X | X |
| Arslan et al. | X | X | X | X |
| Lai et al. | X |
| Shi et al. | X | X |
| Fibroblasts | Borosch et al. | X |
| Cardiomyocytes | X. Wang et al. | X | X | X | X | X |
| Garcia et al. | X | X |
| Ribeiro-Rodrigues et al. | X | X |
| Body fluids | Vicencio et al. | X | X |
| Ma et al. | X |
| X. Wang et al. | X | X |
| Giricz et al. | X |
| Davidson et al. | X | X |
| Minghua et al. | X | X | X | X |
| Wider et al. | X |
| Other cell types | Y. Wang et al. | X | X | X |
| Balhi et al. | X | X | X | X | X |
| Kang et al. | X | X | X | X | X |
| Gu et al. | X | X | X | X |
| Vandergriff et al. | X | X | X | X |
| Ong et al. | X | X | X | X | X |
| Davidson et al. | X |

Table 9. Summary of all publications which investigated the protective effects of extracellular vesicles (EVs) sorted by the EV source. The effect of EVs derived from the indicated source are indicated as follows: ↓ indicates a reduction, ↑ indicates an elevation/activation. LDH: Lactate dehydrogenase, CPCs: cardiac progenitor cells, CDCs: cardiosphere derived cells, MSCs: mesenchymal stem cells.
The following search strategy was applied to identify matching studies:

1. Cochrane Central Register of Controlled Trials in the Cochrane Library;
2. MEDLINE (Ovid, 1946 to May week 4, 2018);
3. Web of Science Core Collection (Thomson Reuters, 1900 to May 24th, 2018).

The following search strategy was applied to identify matching studies:

1. extracellular vesicle OR EV OR exosome OR microvesicle
2. cardio OR cardiac OR heart OR cardioprotection
3. protection OR conditioning

Figure 2. Summary of in EVs encapsulated molecules mediating cardio protective or detrimental impact. Molecules are ordered by origin. Thumbs up indicate a general positive impact of EVs derived from the particular source. Thumbs down indicate a detrimental impact. Effector molecules surrounded by solid lines are specific for a positive impact whereas a dashed line stands for molecules with a negative impact. Proteins are surrounded by a circle, miRNAs by a rectangle.

Figure 3. Forest plots showing the results of meta-analysis of the effect of formation of new capillaries upon a treatment with EVs. Data are expressed as standard mean difference with 95% confidence interval.

Figure 4. Forest plots showing the results of meta-analysis of the effect of protecting cardiomyocytes from hypoxia-reoxygenation injury after a treatment with EVs. Data are expressed as mean difference with 95% confidence interval.
We checked the quality of the included studies by screening the purification methods, methodology to assess EV markers and the presence of electron microscopy (EM) pictures to visualize EV characteristics.

**Dealing with missing data.** Investigators were contacted to obtain missing numerical data and to verify key study characteristics.

**Measures of treatment effect.** We analysed dichotomous data as risk ratios (RR) with 95% confidence intervals (CI). For continuous data, we used the mean difference (MD) with 95% CI for outcomes measured in the same way between trials. We used the standardized mean difference (SMD) with 95% CI to combine data where the same outcome was measured but using different scales. Data reported as medians and interquartile ranges are merely described narratively, since they are presumably skewed distributed.

**Data synthesis.** Statistical analyses were conducted with RevMan 5.3. Meta-analyses were only performed where appropriate. We made sure that the underlying question, EV source, and application as well as experimental setting were similar enough for pooling data. We used fixed-effects meta-analyses to produce a summary treatment effect across trials. We present the results as the treatment effect with its 95% confidence interval, and the estimates of $T^2$ and $Q$.

**Reaching conclusion.** Our conclusion is based on findings from the quantitative or narrative synthesis of included articles for this review. Suggestions are based on the intention to address uncertainties regarding EV purification as well as the performed experiments to investigate EV mediated protection to ensure a greater homogeneity in EV research to enable comparison across studies.

**References**

1. World Health Organization. Cardiovascular diseases (CVDs). http://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (2017).
2. Frank, A. et al. Myocardial ischemia reperfusion injury: from basic science to clinical bedside. *Semin Cardiothorac Vasc Anesth* **16**, 123–132, https://doi.org/10.1053/j.scva.2012.09.002 (2012).
3. Hausenloy, D. J. et al. Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blind controlled clinical trial. *Clin Res Cardiol* **101**, 339–348, https://doi.org/10.1007/s00392-011-0397-x (2012).
4. Goetzenich, A. et al. The role of macrophage migration inhibitory factor in anesthetic-induced myocardial preconditioning. *Plos One* **9**, e92827, https://doi.org/10.1371/journal.pone.0092827 (2014).
5. Goetzenich, A. et al. The role of hypoxia-inducible factor-alpha and vascular endothelial growth factor in late-phase preconditioning with xenon, isoflurane and levsimendan in rat cardiomyocytes. *Interact Cardiovasc Thorac Surg* **18**, 321–328, https://doi.org/10.1093/icvts/ivt450 (2014).
6. Gyorgy, B. et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. *Cell Mol Life Sci* **68**, 2667–2688, https://doi.org/10.1007/s00018-011-0689-3 (2011).
7. Vicencio, J. M. et al. Plasma exosomes protect the myocardium from ischemia-reperfusion injury. *J Am Coll Cardiol* **65**, 1525–1536, https://doi.org/10.1016/j.jacc.2015.02.026 (2015).
8. Giricz, Z. et al. Cardioprotection by remote ischemic preconditioning of the rat heart is mediated by extracellular vesicles. *J Mol Cell Cardiol* **68**, 75–78, https://doi.org/10.1016/j.yjmcc.2014.01.004 (2014).
9. Wang, X. et al. Exosomal miR-223 Contributes to Mesenchymal Stem Cell-Elicited Cardioprotection in Polymicrobial Sepsis. *Sci Rep* **5**, 13721, https://doi.org/10.1038/srep13721 (2015).
10. Feng, Y., Huang, W., Wani, M., Xu, X. & Ashraf, M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mcp2 via miR-22. *Plos One* **9**, e88685, https://doi.org/10.1371/journal.pone.0088685 (2014).
11. Lotvall, J. et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. *J Extracell Vesicles* **3**, 26913, https://doi.org/10.3402/jev.v3.26913 (2014).
12. Consortium, E.-T. et al. EV-TRACK: transparent reporting and centralizing knowledge in extracellular vesicle research. *Nat Methods* **14**, 228–232, https://doi.org/10.1038/nmeth.4185 (2017).
13. Barile, L. et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. *Cardiovasc Res* **103**, 330–341, https://doi.org/10.1093/cvr/cvu167 (2014).
14. Kang, T. et al. Adipose-Derived Stem Cells Induce Angiogenesis via Microvesicle Transport of miRNA-31. *Stem cells translational medicine* **5**, 440–450, https://doi.org/10.9866/stcm.2015.0177 (2016).
15. Ma, F., Liu, H., Shen, Y., Zhang, Y. & Pan, S. Platelet-derived microvesicles are involved in cardioprotective effects of remote preconditioning. *International journal of clinical and experimental pathology* **8**, 10832–10839 (2015).
16. Svennerholm, K. et al. DNA Content in Extracellular Vesicles Isolated from Porcine Coronary Venous Blood Directly after Myocardial Ischemic Preconditioning. *Plos One* **11**, e0159105, https://doi.org/10.1371/journal.pone.0159105 (2016).
17. Bang, C. et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. *J Clin Invest* **124**, 2136–2146, https://doi.org/10.1172/JCI70577 (2014).
18. Cheow, E. S. et al. Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury. *Molecular & cellular proteomics: MCP* **15**, 2628–2640, https://doi.org/10.1074/mcp.M115.055731 (2016).
19. Gu, S. et al. EPC-derived microvesicles protect cardiomyocytes from Ang II-induced hypertrophy and apoptosis. *Plos One* **9**, e85396, https://doi.org/10.1371/journal.pone.0085396 (2014).
20. Lai, R. C. et al. Exosomes secreted by MSC reduces myocardial ischemia/reperfusion injury. *Stem Cell Res* **4**, 214–222, https://doi.org/10.1016/j.scr.2009.12.003 (2010).
21. Garcia, N. A., Oortia-Oviedo, I., Gonzalez-King, H., Diez-Juan, A. & Sepulveda, P. Glucose Starvation in Cardiomyocytes Enhances Exosome Secretion and Promotes Angiogenesis in Endothelial Cells. *Plos One* **10**, e0138849, https://doi.org/10.1371/journal.pone.0138849 (2015).
22. Gray, W. D. et al. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. *Circ Res* **116**, 255–263, https://doi.org/10.1161/CIRCRESAHA.116.304360 (2015).
23. Zhao, Y. et al. Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Relieve Acute Myocardial Ischemic Injury. *Stem Cells Int* **2015**, 761643, https://doi.org/10.1155/2015/761643 (2015).
24. Wang, X. et al. Hsp20-Mediated Activation of Exosome Biogenesis in Cardiomyocytes Improves Cardiac Function and Angiogenesis in Diabetic Mice. *Diabetes* **65**, 3111–3128, https://doi.org/10.2337/db15-1563 (2016).
25. Namazi, H. et al. Exosomes Secreted by Normoxic and Hypoxic Cardiomyocyte-derived Cells Have Anti-apoptotic Effect. Iran J Pharm Res 17, 377–385 (2018).
26. Balbi, C. et al. First Characterization of Human Amniotic Fluid Stem Cell Extracellular Vesicles as a Powerful Paracrine Tool Endowed with Regenerative Potential. Stem cells translational medicine 6, 1340–1355, https://doi.org/10.1002/sctm.16-0297 (2017).
27. Davidson, S. M. et al. Cardioprotection mediated by exosomes is impaired in the setting of type II diabetes but can be rescued by the use of non-diabetic exosomes in vitro. J Cell Mol Med 22, 141–151, https://doi.org/10.1111/jcmm.13302 (2018).
28. Namazi, H. et al. Exosomes secreted by hypoxic cardiomyocyte-derived cells enhance tube formation and increase pro-angiogenic miRNA. J Cell Biochem 119, 4150–4160, https://doi.org/10.1002/jcb.26621 (2018).
29. Obata, Y. et al. Adiponectin/T-cadherin system enhances exosome biogenesis and decreases cellular ceramides by exosomal release. JCI Insight 3, https://doi.org/10.1172/jci.insight.99680 (2018).
30. Ribeiro-Rodrigues, T. M. et al. Exosomes secreted by cardiomyocytes subjected to ischaemia promote cardiac angiogenesis. Cardiovasc Res 113, 1338–1350, https://doi.org/10.1093/cvr/cvx118 (2017).
31. Svennerholm, K. et al. Myocardial ischemic preconditioning in a porcine model leads to rapid changes in cardiac extracellular vesicle messenger RNA content. Int J Cardiol Heart Vasc 8, 62–67, https://doi.org/10.1016/j.ijhcv.2015.05.006 (2015).
32. Wider, I. et al. Remote ischemic preconditioning fails to reduce infarct size in the Zucker fatty rat model of type-2 diabetes: role of defective humoral communication. Basic research in cardiology 113, 16, https://doi.org/10.1007/s00395-018-0674-1 (2018).
33. Ibrahim, A. G., Cheng, K. & Marban, E. Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Circ Res 119, 970–974, https://doi.org/10.1161/CIRCRESAHA.114.302982 (2016).
34. Chen, L. et al. Cardiomyocyte protection by GATA-4 gene engineered mesenchymal stem cells is partially mediated by translocation of miR-21 in microvesicles. PloS One 8, e73304, https://doi.org/10.1371/journal.pone.0073304 (2013).
35. Shi, B. et al. Bone marrow mesenchymal stem cell-derived exosomal miR-21 protects C-kit + cardiac stem cells from oxidative injury through the PTEN/Pi3k/Akt axis. Plos One 13, e0191616, https://doi.org/10.1371/journal.pone.0191616 (2018).
36. Minna, W. et al. Plasma exosomes induced by remote ischaemic preconditioning attenuate myocardial ischaemia/reperfusion injury by transferring miR-24. Cell Death Dis 9, 320, https://doi.org/10.1038/cddis.2018.074 (2018).
37. Arslan, F. et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res 10, 301–312, https://doi.org/10.1016/j.scr.2013.01.002 (2013).
38. Vandergriff, A. C. et al. Intraoperative delivery of GATA 4 exosomes ameliorates cardiac dysfunction in Doxorubicin Induced Dilated Cardiomyopathy. Stem Cells Int 2015, 960926, https://doi.org/10.1155/2015/960926 (2015).
39. Zhou, P. & Wu, W. Reconstituting Cardiac Cellular Composition. Circ Res 118, 368–370, https://doi.org/10.1161/CIRCRESAHA.116.308199 (2016).
40. Hsieh, P. C. et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 13, 970–974, https://doi.org/10.1038/nm1618 (2007).
41. Senyo, S. E. et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 493, 433–436, https://doi.org/10.1038/nature11682 (2013).
42. Smith, R. R. et al. Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 13, 970–974, https://doi.org/10.1038/nm1618 (2007).
43. Senyo, S. E. et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 493, 433–436, https://doi.org/10.1038/nature11682 (2013).
44. Menck, K. et al. Neutral sphingomyelinases control extracellular vesicles budding from the plasma membrane. J Extracell Vesicles 6, 1370856, https://doi.org/10.1080/20013078.2017.1370856 (2017).
45. Tejakovic, K. et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319, 1244–1247, https://doi.org/10.1126/science.1135324 (2008).
46. Baudino, T. A., Carver, W., Giles, W. & Borg, T. K. Cardiac fibroblasts: friend or foe? American journal of physiology. Heart and circulatory physiology 291, H1015–1026, https://doi.org/10.1152/ajpheart.00023.2006 (2006).
47. Park, C. W. et al. Cytokine secretion profiling of human mesenchymal stem cells by antibody array. Int J Stem Cells 2, 59–68 (2009).
48. Zhao, H., Dupont, J., Yakar, S., Kaufman, D. & Loeb, D. PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells. Oncogene 23, 786–794, https://doi.org/10.1038/sj.onc.1207162 (2004).
49. Essandoh, K. et al. Blockade of exosome ejection with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. Biochim Biophys Acta 1852, 2362–2371, https://doi.org/10.1016/j.bbadis.2015.08.010 (2015).
50. Wu, S. H. et al. Therapeutic effects of human adipose-derived products on impaired wound healing in irradiated tissue. Plast Reconstr Surg. https://doi.org/10.1097/PRS.0000000000000609 (2018).
51.不出来, A. W. et al. Methodological Guidelines to Study Extracellular Vesicles. Circ Res 120, 1632–1648, https://doi.org/10.1161/CIRCRESAHA.117.309417 (2017).
52. Kowal, I. et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci USA 113, E986–977, https://doi.org/10.1073/pnas.1521230113 (2016).
65. Sluijter, J. P. G. et al. Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 114, 19–34, https://doi.org/10.1093/cvr/cvx211 (2018).

66. Davidson, S. M. & Yellon, D. M. Exosomes and cardioprotection - A critical analysis. Mol Aspects Med 60, 104–114, https://doi.org/10.1016/j.mam.2017.11.004 (2018).

67. Lobb, R. J. et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 4, 27031, https://doi.org/10.3402/jev.v4.27031 (2015).

68. Baranayi, T. et al. Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods. Plos One 10, e0145686, https://doi.org/10.1371/journal.pone.0145686 (2015).

69. Witek, P. et al. The effect of a number of H9C2 rat cardiomyocytes passage on repeatability of cytotoxicity study results. Cytotechnology 68, 2407–2415, https://doi.org/10.1007/s10616-016-9957-2 (2016).

70. Branco, A. F. et al. Gene Expression Profiling of H9c2 Myoblast Differentiation towards a Cardiac-Like Phenotype. Plos One 10, e0129303, https://doi.org/10.1371/journal.pone.0129303 (2015).

71. Chen, L. et al. BMSCs-derived miR-223-containing exosomes contribute to liver protection in experimental autoimmune hepatitis. Mol Immuno/93, 38–46, https://doi.org/10.1016/j.molimm.2017.11.008 (2018).

72. Jia, P. et al. MicroRNA-21 Is Required for Local and Remote Ischemic Preconditioning in Multiple Organ Protection Against Sepsis. Crit Care Med 45, e703–e710, https://doi.org/10.1097/CCM.0000000000002363 (2017).

73. Coakley, G., Maizels, R. M. & Buck, A. H. Exosomes and Other Extracellular Vesicles: The New Communicators in Parasite Infections. Trends Parasitol 31, 477–489, https://doi.org/10.1016/j.pt.2015.06.009 (2015).

74. Higgins, J. & Green, S. (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from, handbook.cochrane.org (2011).

Acknowledgements
We thank all authors for kindly providing additional information and data, regarding their studies, for this systematic review/meta-analysis. This research project is supported by the START-Program of the Faculty of Medicine, RWTH Aachen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions
Wrote the manuscript (S.W.). Development of concept and design of the study (S.W., S.K., C.Be., C.S., A.G.). Screening titles, abstracts and full texts for eligibility in this systematic review/meta-analysis (S.W., S.K., C.S.). Data extraction (S.W., S.K.). Design of the meta-analysis and interpretation of the results (S.W., C.Be.). Critical revision of the manuscript (S.W., C.G., S.K., C.Be., A.G., C.S., C.Bl.). All authors contributed significant intellectual input to the manuscript and approved the final version for publication.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-33862-5.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018